Current treatments for breast cancer depend on estrogen receptor(ER), Progesterone receptor (PR), and Human epidermal growth factor receptor2 (HER2) status (López-Knowles et al., 2010; Khan et al., 2018).Knowledge of clinicopathological parameters such as tumor size, tumor grade, and lymph node involvement status is essential in clinical decision making for the patient (Wang et al., 2015). This evidence concerns the gene PGR and breast cancer.